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Problem of antibiotic resistance in patients with acute bacterial
cystitis and treatment options
Ahmet KARAKAŞ1, Vedat TURHAN2

Acute bacterial cystitis (ABC) is one of the most common community-acquired (CA)
infections. We curiously read the systematic analysis article “Management of community-acquired
acute bacterial cystitis in Turkey” by Coşkun et al. about determining the adequate antibiotherapy
for ABC in our country (1).
That study objectively revealed the potential antibiotherapy resistance generally assigned by
clinicians based on long-term personal experience and dissolved the suspicions. Accordingly,
trimethoprim-sulfamethoxazole (SXT), amoxicillin-clavulanate (AMC), and 1st and 2nd
generations of cephalosporins that are used empirically in Turkey are not reliable because serious
resistance has been detected for antibiotics used in the traditional treatment of CA-ABC. For
example, more than 20% resistance is suggested for SXT, amoxicillin-clavulanate, cefazolin, and
cefuroxime. With this study, fosfomycin and nitrofurantoin were shown to have an excellent effect
on E. coli, the most common agent for CA-ABCs. This systematic analysis showed resistance rates
of more than 20% for quinolones like ciprofloxacin that are widely used in Turkey for adult ABC.
On the other hand, aminoglycosides, 3rd and 4th generation cephalosporins, and piperacillintazobactam were found to be more reliable. However, none of these antibiotics can be comfortably
used for outpatients. For that reason, fosfomycin and nitrofurantoin are the antibiotics that should
be essentially used in place of the aforementioned ones. Antibiotic resistance generally is not
an important issue for patients with first-attack CA-ABC. In these cases, despite the resistance
to amoxicillin, ampicillin, or SXT, sensitivity to 3rd generation cephalosporins or quinolones is
expected. However, quinolone resistance is often found in patients with recurrent ABC attacks.
In such cases, bad sanitation or an underlying cause like ureterovesical reflux, urinary spasm,
or nephrolithiasis may be present. In relatively elderly patients, obesity and diabetes mellitus are
significant predisposing factors. In ABC cases with an underlying risk or patient cooperation
problems, initiation of oral antibiotics like nitrofurantoin or fosfomycin empirically (until the
urine culture results are obtained) may be reasonable.
Azap et al. reported extended-spectrum β-lactamase (ESBL) positivity of 6.3% (17 of 269) in
noncomplicated CA-urinary tract infections (CA-UTI) cases and of 17.4% (34 of 195) in complicated
CA-UTI cases in their 2010 study of 510 CA-UTI cases. In the same study, SXT, ciprofloxacin, and
gentamicin resistance was found to be low in the ESBL-negative group at 4.6%, but this rate was 8
times higher in the ESBL-positive group (39.2%, P < 0.001) (2). However, this finding should not
mean the initiation of carbapenem therapy in cases of CA-UTI caused by ESBL-positive members
of Enterobacteriaceae. Noncarbapenem antibiotics (AMC, piperacillin-tazobactam, 3rd and 4th
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generation cephalosporins, etc.) may be used in
these cases. With its 2009 regulation, the European
Committee on Antimicrobial Susceptibility Testing
(EUCAST) focused on the definition “ESBL (+)
Enterobacteriaceae” for the species isolated from
UTIs, redefined the sensitivity zone radius and MIC
values for 3rd and 4th generation cephalosporins
(cefotaxime, ceftriaxone, ceftazidime, and cefepime),
and suggested the use of noncarbapenem antibiotics
in case of sensitivity (3).
Pullukcu et al. administered oral fosfomycin (3 g
each 48 h, repeated for 3 doses) for 52 ESBL producers
in cases with no systemic signs or symptoms (mean
patient age: 55 ± 18.3 years), and 94% of patients
responded well clinically. Microbiological response
was obtained in 78% of the cases. Upon the 1-month
follow-up, none of the patients showed a relapse.
Meanwhile, 70% of the study group had risk factors
including indwelling catheter, hemiparesis or
quadriparesis, malignancy in urinary tract, other
malignancies, diabetes mellitus, renal transplantation,
nephrolithiasis, and recent urological intervention
(4). Similar findings were also reported by some
other researchers (5,6).

This approach forms an important treatment
alternative for many centers with outpatients. It is
a fact that fosfomycin is preferred more often for
such cases today in Turkey. In cases of urinary tract
infections by ESBL-positive Enterobacteriaceae,
fosfomycin will thus be encountered as a carbapenemsparing agent. Our personal observation depicts
the positivity of this approach in obviating the
unnecessary hospitalization of ABC patients and
carbapenem dependence. As the development of new
antibiotics declines, effective use of ‘old’ antibiotics
and dynamic following of changes in antibiotic
resistance have gained more importance. Prevention
against ABC and the use of products from medicinal
plants like cranberry will also ease the management
of CA-ABC. In their study of 153 female patients,
Avorn et al. reported that daily consumption of
300 mL of cranberry juice decreased bacteriuria
and pyuria frequency by 42% (7). It was suggested
to prevent the adherence of E. coli fimbrial subunits
to the uroepithelium by competitive inhibition or
blocking of fimbrial subunit functions (8).
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